ADMA Biologics Inc (ADMA) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Total Assets Chart for ADMA Biologics Inc
ADMA Biologics Inc (ADMA) total assets for FY2025 were USD 624.2M, a 27.7% change from FY2024. ADMA Biologics Inc's total assets grew from USD 14.7M in 2006 to USD 624.2M in 2025 (4160.5% over 19 years). Total assets compound annual growth rate: 5-year CAGR of 24.6%, 10-year CAGR of 38.7%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $2.39B
- Implied Share Price
- $10.68
- Enterprise Value
- $2.24B
- Revenue (TTM)
- $512.28M
- EBITDA
- $224.19M
- Profit Margin
- 32.98%
- Trailing P/E
- 15.26
- Forward P/E
- 9.78
- Price/Book (MRQ)
- 5.32
- Price/Sales (TTM)
- 4.67
- EV/EBITDA
- 9.61
- EV/Revenue
- 4.37
- Dividend Yield
- —
- Book Value
- $1.81
- Free Cash Flow (FY2025)
- $27.82M
- Free Cash Flow Yield
- 1.16%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.